Giuseppe
Emeritus
[Source: Science Direct, full page: (LINK). Abstract, edited.]
Virology, Volumes 452?453, March 2014, Pages 32?41
Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein
Nicolas Escriou<SUP>a</SUP><SUP>, </SUP><SUP>c</SUP><SUP>, </SUP><SUP>d</SUP><SUP>, </SUP><SUP>1</SUP>, Beno?t Callendret<SUP>a</SUP><SUP>, </SUP><SUP>c</SUP><SUP>, </SUP><SUP>d</SUP>, Val?rie Lorin<SUP>a</SUP><SUP>, </SUP><SUP>c</SUP><SUP>, </SUP><SUP>d</SUP><SUP>, </SUP><SUP>1</SUP>, Chantal Combredet<SUP>b</SUP><SUP>, </SUP><SUP>c</SUP>, Philippe Marianneau<SUP>e</SUP>, Mich?le F?vrier<SUP>b</SUP><SUP>, </SUP><SUP>c</SUP>, Fr?d?ric Tangy<SUP>b</SUP><SUP>, </SUP><SUP>c</SUP>
<SUP></SUP>
<SUP>a</SUP> Institut Pasteur, Unit? de G?n?tique Mol?culaire des Virus ? ARN, D?partement de Virologie, F-75015 Paris, France; <SUP>b</SUP> Institut Pasteur, Unit? de G?nomique Virale et Vaccination, D?partement de Virologie, F-75015 Paris, France; <SUP>c</SUP> CNRS, UMR 3569, F-75015 Paris, France; <SUP>d</SUP> Univ. Paris Diderot, Sorbonne, Paris Cit?, EA 302, F-75015 Paris, France; <SUP>e</SUP> Institut Pasteur, Unit? de Biologie des Infections Virales Emergentes, D?partement de Virologie, F-69007 Lyon, France
Received 21 October 2013 - Revised 7 November 2013 - Accepted 3 January 2014 - Available online 28 January 2014
http://dx.doi.org/10.1016/j.virol.2014.01.002
Highlights
Abstract
The recent identification of a novel human coronavirus responsible of a SARS-like illness in the Middle-East a decade after the SARS pandemic, demonstrates that reemergence of a SARS-like coronavirus from an animal reservoir remains a credible threat. Because SARS is contracted by aerosolized contamination of the respiratory tract, a vaccine inducing mucosal long-term protection would be an asset to control new epidemics. To this aim, we generated live attenuated recombinant measles vaccine (MV) candidates expressing either the membrane-anchored SARS-CoV spike (S) protein or its secreted soluble ectodomain (Ssol). In mice susceptible to measles virus, recombinant MV expressing the anchored full-length S induced the highest titers of neutralizing antibodies and fully protected immunized animals from intranasal infectious challenge with SARS-CoV. As compared to immunization with adjuvanted recombinant Ssol protein, recombinant MV induced stronger and Th1-biased responses, a hallmark of live attenuated viruses and a highly desirable feature for an antiviral vaccine.
Keywords
Coronavirus; Severe acute respiratory syndrome; Spike glycoprotein; Measles vaccine
Correspondence to: Unit? de G?nomique Virale et Vaccination, Institut Pasteur, 25-28 rue du Dr. Roux, 75724 Paris Cedex 15, France. Tel.: +33 1 40613901; fax: +33 1 40613167.
Correspondence to: Unit? de G?nomique Virale et Vaccination, Institut Pasteur, 25-28 rue du Dr. Roux, 75724 Paris Cedex 15, France. Tel.: +33 1 45688770; fax: +33 1 40613167.
1 Present address: Institut Pasteur, Unit? de G?nomique Virale et Vaccination, D?partement de Virologie, F-75015 Paris, France.
Copyright ? 2014 Elsevier Inc. All rights reserved.
-
------
Virology, Volumes 452?453, March 2014, Pages 32?41
Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein
Nicolas Escriou<SUP>a</SUP><SUP>, </SUP><SUP>c</SUP><SUP>, </SUP><SUP>d</SUP><SUP>, </SUP><SUP>1</SUP>, Beno?t Callendret<SUP>a</SUP><SUP>, </SUP><SUP>c</SUP><SUP>, </SUP><SUP>d</SUP>, Val?rie Lorin<SUP>a</SUP><SUP>, </SUP><SUP>c</SUP><SUP>, </SUP><SUP>d</SUP><SUP>, </SUP><SUP>1</SUP>, Chantal Combredet<SUP>b</SUP><SUP>, </SUP><SUP>c</SUP>, Philippe Marianneau<SUP>e</SUP>, Mich?le F?vrier<SUP>b</SUP><SUP>, </SUP><SUP>c</SUP>, Fr?d?ric Tangy<SUP>b</SUP><SUP>, </SUP><SUP>c</SUP>
<SUP></SUP>
<SUP>a</SUP> Institut Pasteur, Unit? de G?n?tique Mol?culaire des Virus ? ARN, D?partement de Virologie, F-75015 Paris, France; <SUP>b</SUP> Institut Pasteur, Unit? de G?nomique Virale et Vaccination, D?partement de Virologie, F-75015 Paris, France; <SUP>c</SUP> CNRS, UMR 3569, F-75015 Paris, France; <SUP>d</SUP> Univ. Paris Diderot, Sorbonne, Paris Cit?, EA 302, F-75015 Paris, France; <SUP>e</SUP> Institut Pasteur, Unit? de Biologie des Infections Virales Emergentes, D?partement de Virologie, F-69007 Lyon, France
Received 21 October 2013 - Revised 7 November 2013 - Accepted 3 January 2014 - Available online 28 January 2014
http://dx.doi.org/10.1016/j.virol.2014.01.002
Highlights
- Generation of live recombinant measles vaccine expressing SARS-CoV spike protein.
- Induction of high titers anti-SARS-CoV neutralizing antibodies in mice.
- Protection of immunized mice from intranasal infectious challenge with SARS-CoV.
- Induction of Th1-biased responses and IgA.
Abstract
The recent identification of a novel human coronavirus responsible of a SARS-like illness in the Middle-East a decade after the SARS pandemic, demonstrates that reemergence of a SARS-like coronavirus from an animal reservoir remains a credible threat. Because SARS is contracted by aerosolized contamination of the respiratory tract, a vaccine inducing mucosal long-term protection would be an asset to control new epidemics. To this aim, we generated live attenuated recombinant measles vaccine (MV) candidates expressing either the membrane-anchored SARS-CoV spike (S) protein or its secreted soluble ectodomain (Ssol). In mice susceptible to measles virus, recombinant MV expressing the anchored full-length S induced the highest titers of neutralizing antibodies and fully protected immunized animals from intranasal infectious challenge with SARS-CoV. As compared to immunization with adjuvanted recombinant Ssol protein, recombinant MV induced stronger and Th1-biased responses, a hallmark of live attenuated viruses and a highly desirable feature for an antiviral vaccine.
Keywords
Coronavirus; Severe acute respiratory syndrome; Spike glycoprotein; Measles vaccine
Correspondence to: Unit? de G?nomique Virale et Vaccination, Institut Pasteur, 25-28 rue du Dr. Roux, 75724 Paris Cedex 15, France. Tel.: +33 1 40613901; fax: +33 1 40613167.
Correspondence to: Unit? de G?nomique Virale et Vaccination, Institut Pasteur, 25-28 rue du Dr. Roux, 75724 Paris Cedex 15, France. Tel.: +33 1 45688770; fax: +33 1 40613167.
1 Present address: Institut Pasteur, Unit? de G?nomique Virale et Vaccination, D?partement de Virologie, F-75015 Paris, France.
Copyright ? 2014 Elsevier Inc. All rights reserved.
-
------